Hitting the Target in HER2-Positive Metastatic Colorectal Cancer is organized by i3 Health and will be held from June 13, 2023 - June 12, 2024.
Statement of Need:
An estimated 153,020 new cases of colorectal cancer (CRC) are diagnosed annually, and 52,550 people die of the disease (Siegel et al, 2023). Approximately 22% of patients present with metastatic disease, which is associated with a dismal 5-year survival rate of 15% (SEER, 2022). Targeting biomarkers is a key strategy for expanding therapeutic options and improving outcomes in metastatic CRC. Human epidermal growth factor receptor 2 (HER2) amplification status and treatments targeting HER2 are some of the most recent additions to the arsenal of targeted therapy for this disease. This activity chaired by Christopher Lieu, MD, Associate Director of Clinical Research at the University of Colorado Cancer Center, will provide expert perspectives and practical guidance on treating HER2-positive metastatic CRC.
Learning Objectives:
Upon completion of this activity, participants should be able to
- Distinguish actionable targets that can inform personalized care plans in metastatic CRC
- Evaluate practice guidelines on treatment combinations and sequences for patients with metastatic CRC
- Appraise emerging efficacy and safety data on novel targeted therapies for patients with HER2-positive metastatic CRC
- Assess strategies for optimizing the safety and tolerability of novel targeted therapies for HER2-positive metastatic CRC
In this activity, hear about the latest data and strategies for hitting the target in HER2-positive metastatic colorectal cancer. Dr. Christopher Lieu, Associate Professor at the University of Colorado Cancer Center, explores actionable targets to inform personalized care plans, guideline-recommended combination and sequencing strategies, adverse event monitoring and management, and more. Start the activity now!
Faculty:
Christopher Lieu, MD
Associate Professor
Associate Director, Clinical Research
University of Colorado Cancer Center